agalsidase alfa

Ukraine

Drugs containing this active substance

REPLAGAL

The drug is intended for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase deficiency).

Form: concentrate for infusion solution

Active substance	Dosage
agalsidase alfa	1 mg/ml

Manufacturer: Shire Pharmaceuticals Ireland Limited (responsible for batch release) / Takeda Pharmaceuticals International AG Ireland Branch (responsible for batch release)